BioCardia (BCDA) News Today → This unknown company solves the biggest issue with AI (From Manward Press) (Ad) Free BCDA Stock Alerts $0.39 -0.01 (-2.49%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 5:23 AM | finanznachrichten.deBioCardia, Inc.: BioCardia Reports First Quarter 2024 Business Highlights and Financial ResultsMay 15 at 5:23 AM | finance.yahoo.comBioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ...May 14 at 9:04 PM | investorplace.comBCDA Stock Earnings: BioCardia Reported Results for Q1 2024May 14 at 4:02 PM | globenewswire.comBioCardia Reports First Quarter 2024 Business Highlights and Financial ResultsMay 14 at 6:47 AM | finance.yahoo.comMost Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is ReasonableMay 12, 2024 | americanbankingnews.comBioCardia (BCDA) Scheduled to Post Earnings on TuesdayMay 9, 2024 | globenewswire.comBioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024May 1, 2024 | finance.yahoo.comBioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important OutcomesMay 1, 2024 | globenewswire.comBioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important OutcomesApril 25, 2024 | globenewswire.comBioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In CohortApril 1, 2024 | finance.yahoo.comBioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial ResultsMarch 29, 2024 | finance.yahoo.comBioCardia Full Year 2023 Earnings: Misses ExpectationsMarch 28, 2024 | benzinga.comPreview: BioCardia's EarningsMarch 28, 2024 | markets.businessinsider.comBioCardia is about to announce its earnings — here's what to expectMarch 28, 2024 | finance.yahoo.comQ4 2023 BioCardia Inc Earnings CallMarch 27, 2024 | benzinga.comBioCardia: Q4 Earnings InsightsMarch 27, 2024 | globenewswire.comBioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial ResultsMarch 20, 2024 | money.usnews.comBioCardia Inc.March 20, 2024 | globenewswire.comBioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024March 13, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia and StemCardia Announce Biotherapeutic Delivery PartnershipMarch 13, 2024 | globenewswire.comBioCardia and StemCardia Announce Biotherapeutic Delivery PartnershipMarch 12, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure StudyMarch 12, 2024 | msn.comBioCardia spikes after Medicare coverage for cell therapy trialMarch 12, 2024 | globenewswire.comBioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure StudyMarch 4, 2024 | markets.businessinsider.comBioCardia Reports Positive Interim Results From Phase III CardiAMP Cell Therapy Heart Failure TrialMarch 4, 2024 | globenewswire.comBioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart FailureFebruary 27, 2024 | finance.yahoo.comBCDA Mar 2024 1.500 callFebruary 17, 2024 | finance.yahoo.comBCDA Aug 2024 0.500 callFebruary 17, 2024 | finance.yahoo.comBCDA Mar 2024 0.500 callFebruary 10, 2024 | msn.comBioCardia Inc Secures Funding Through Private PlacementFebruary 10, 2024 | msn.comBioCardia Inc Conducts Unregistered Equity Securities SaleFebruary 9, 2024 | msn.comBioCardia Launches Pivotal CardiAMP HF II TrialFebruary 8, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDAFebruary 8, 2024 | finance.yahoo.comBioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDAFebruary 1, 2024 | msn.comBioCardia to Present CardiAMP and CardiALLO at ConferenceJanuary 31, 2024 | finance.yahoo.comBioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics ConferenceJanuary 3, 2024 | finance.yahoo.comBioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for ShareholdersJanuary 1, 2024 | finance.yahoo.comPositive Signs As Multiple Insiders Buy BioCardia StockDecember 22, 2023 | benzinga.comBioCardia Stock (NASDAQ:BCDA) Dividends: History, Yield and DatesDecember 19, 2023 | finance.yahoo.comBioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection FractionDecember 18, 2023 | finance.yahoo.comBioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation MinutesNovember 29, 2023 | finance.yahoo.comBioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product ApprovalNovember 16, 2023 | finance.yahoo.comBioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesNovember 15, 2023 | msn.comBioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure StudyNovember 14, 2023 | msn.comCrude Oil Moves Higher; Beauty Health Shares PlungeNovember 14, 2023 | msn.com200% Gain In One Day - Why Is Heart Failure Focused BioCardia Stock Soaring Today?November 14, 2023 | benzinga.comNasdaq Surges 2%; US Inflation Rate Slows In OctoberNovember 14, 2023 | marketbeat.comTrading was temporarily halted for "BCDA" at 09:11 AM with a stated reason of "LULD pause." Trading set to resume at 09:11 AM. November 14, 2023 | markets.businessinsider.comBioCardia: FDA Approves CardiAMP Heart Failure II Protocol For Autologous Cell Therapy Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street legend who predicted 2021 tech crash issues new warning (Ad)People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history. Watch his stock warning right here, 100% free of charge BCDA Media Mentions By Week BCDA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCDA News Sentiment▼0.610.54▲Average Medical News Sentiment BCDA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCDA Articles This Week▼101▲BCDA Articles Average Week Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GENE News ONVO News IKT News COEP News SRNE News TVGN News CELZ News TTNP News PALI News FRTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCDA) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressWall Street legend who predicted 2021 tech crash issues new warningChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop 5 Tech Stocks to Buy for 2024Daily Market AlertsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
